BRKRP — Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
US
$435.13
+$19.97 (+4.81%)
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP) common stock listed on US. It is with about 11,396 employees. Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
Latest reported BRKRP revenue for 2025-09-30 was $860.5M. Net income was -$58.5M. Revenue was up 7.9% from 2025-06-30 to 2025-09-30.
Use this BRKRP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BRKRP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BRKRP SEC filings page. Lician reads the product cache first so this HTML stays unique to Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A even when a live quote feed is slow.
About Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
BRKRP Key Statistics
Market Cap
$0.00M
Volume
751
Previous Close
$423.01
Day Range
$419.29 – $424.22
EPS
$0.76
Revenue
$3.37B
Net Income
$113.80M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+13.6%
Profit Margin
3.4%
Employees
11,396
BRKRP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $3.37B | $2.96B | $2.53B | $2.42B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $113.80M | $428.50M | $298.50M | $280.60M |
| EPS (Diluted) | $0.76 | $2.90 | $1.99 | $1.81 |
Total Assets
$5.81B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$183.40M
Operating Cash Flow
$251.30M
Free Cash Flow
$0.00
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A Company Information
- IPO / Founded
- 2025-09-09